Tag: agospharmaceuticals

Agios Pharmaceuticals Announces Phase 3 ENERGIZE – Treatment for Thalassemia Patients

Phase 3 ENERGIZE

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia January 3, 2024 – Agios Pharmaceuticals, Inc. today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of […]

Read more


Secured By miniOrange